Author: Kerry Rowe
– Wearable sensors strongly correlated with clinical scales on motor impairment – – bioMUSE Study Validates Use of Wearable Sensors for Alterity’s Ongoing Phase 2 Clinical Trial – Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced a poster from ...
All stakeholders of Alterity Therapeutics, are invited to register to view the Company’s presentation at the 34th Annual Roth Conference. The conference is taking place Monday, 14 March and Tuesday, 15 March 2022 in Dana Point, California, USA. Link to registration: https://wsw.com/webcast/roth43/athe/1810184
Alterity Therapeutics Investor Presentation 10 April 2019
Alterity Therapeutics Limited, (formerly Prana Biotechnology Limited) is meeting this week with sophisticated investors in both Singapore and Hong Kong in the first leg of a global investor roadshow.
We wish to announce the Company name change has been processed by the Australian Securities and Investment Commission and the Company has changed its name from “Prana Biotechnology Limited” to “Alterity Therapeutics Limited”.
Alterity Therapeutics Limited (formerly Prana Biotechnology Limited) (ASX:PBT) (“Alterity” or “the Company”) is pleased to announce completion of the strategic investment by Life Biosciences LLC (Life) of an initial US$7.5m (A$10.526m at an exchange rate of A$1.00 to US$0.7125) in the Company (Subscription).
The Company wishes to advise that all resolutions contained in the Notice of Meeting were carried on a show of hands.
Prana Biotechnology today advises that a conference call facility will be available at the Extraordinary General Meeting (EGM) scheduled for Friday, April 5, 2019, at 11:00 AM AEDT.
Prana has today announced that is has received a A$3.3 million cash refund under the Australian Government’s R&D Tax Incentive Scheme.